ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Clinical trials for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could removing certain immune cells prevent a devastating transplant complication?
Disease control Recruiting nowThis study is for children and young adults with blood cancers who are getting a donor stem cell transplant. The goal is to see if removing a specific type of immune cell (naive T cells) from the donated cells can prevent chronic graft-versus-host disease, a serious condition whe…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Supercharged donor cells take on viruses in transplant patients
Disease control Recruiting nowThis study tests whether specially trained white blood cells from a donor can safely treat cytomegalovirus (CMV) or adenovirus infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-fighting cells to see if they con…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: EARLY_PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Pre-Transplant fitness program aims to boost recovery in blood cancer patients
Disease control Recruiting nowThis study tests whether a prehabilitation program (exercise and nutrition support) before a stem cell transplant can improve quality of life for blood cancer patients. About 110 adults scheduled for a transplant will be randomly assigned to either the program or standard care. T…
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug cocktail aims to boost transplant success in elderly leukemia patients
Disease control Recruiting nowThis study tests a combination of five drugs (called VABu) given before a stem cell transplant in people aged 60 and older with acute myeloid leukemia (AML). The goal is to see if this approach can help control the disease and improve survival. About 20 participants will receive …
Matched conditions: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT
Phase: PHASE2, PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC